In this respect, inhibition of 3-phosphoglycerate dehydrogenase (PHGDH), the rate limiting enzyme for de novo serine biosynthesis, turned out to be a promising therapeutic strategy to overcome resistance in metabolically-driven cancers (Rathore et al., 2020, 2021; McNamee et al., 2021; Zhao et al., 2021). Here, PHGDH is linked to cancer.